Skip to main content

Table 1 Demographic data (mean ± SEM,n= 42, except when marked otherwise)

From: Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis

Age (years)

61 ± 2.4

Body weight (kg)

84.4 ± 3.2

Body Mass Index kg/m2

29.2 ± 1.2

Length of ICU-Stay (days)

15 ± 2.9

history of HIT

6.0 ± 1.2, n = 23

no history of HIT

25.8 ± 5.0, n = 19

SAPS <30

11 ± 3.0, n = 16

SAPS >30

18 ± 4.2, n = 26

SAPS score on ICU admission

34 ± 2.2

Sepsis

14 (33%)

Renal replacement therapy

17 (40.5%)

Respiratory failure

31 (73.8%)

Veno-arterial ECMO

1 (2.4%)

Death*

6 (14.2%)

  1. *Death was unrelated to bleeding, thromboembolic complication or argatroban.